The Future of Inducement Claims in the Hatch-Waxman Context: Reconciling the Demarcation Between Describing and Infringing Use and Encouraging That Use in a Label


InterContinental New York Times Square

300 W 44th St.

New York, NY 10036

Date & Time

Start Date: 04/26/2022
End Date: 04/27/2022


Aaron Lukas will be moderating at the Paragraph IV Disputes Conference on whether a skinny label alone is enough to preclude induced infringement allegations. Aaron and the panel will also discuss the anticipation of the impact of recent decisions on claim drafting and the availability of generic drugs, devising strategic considerations of label language for inducement infringement, reviewing the approval of generic drug labeling, and assessing the flurry of follow-on cases in the courts.


Share on LinkedIn


Aaron Lukas, Ph.D.

Co-Chair, Hatch-Waxman & Biologics Litigation

(202) 912-4823

Related Practices